Cargando…
High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome
Natural killer (NK) cells are major antileukemic immune effectors. Leukemic blasts have a negative impact on NK cell function and promote the emergence of phenotypically and functionally impaired NK cells. In the current work, we highlight an accumulation of CD56(−)CD16(+) unconventional NK cells in...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179170/ https://www.ncbi.nlm.nih.gov/pubmed/34050021 http://dx.doi.org/10.1073/pnas.2020459118 |
_version_ | 1783703724768624640 |
---|---|
author | Chretien, Anne-Sophie Devillier, Raynier Granjeaud, Samuel Cordier, Charlotte Demerle, Clemence Salem, Nassim Wlosik, Julia Orlanducci, Florence Gorvel, Laurent Fattori, Stephane Hospital, Marie-Anne Pakradouni, Jihane Gregori, Emilie Paul, Magali Rochigneux, Philippe Pagliardini, Thomas Morey, Mathieu Fauriat, Cyril Dulphy, Nicolas Toubert, Antoine Luche, Herve Malissen, Marie Blaise, Didier Nunès, Jacques A. Vey, Norbert Olive, Daniel |
author_facet | Chretien, Anne-Sophie Devillier, Raynier Granjeaud, Samuel Cordier, Charlotte Demerle, Clemence Salem, Nassim Wlosik, Julia Orlanducci, Florence Gorvel, Laurent Fattori, Stephane Hospital, Marie-Anne Pakradouni, Jihane Gregori, Emilie Paul, Magali Rochigneux, Philippe Pagliardini, Thomas Morey, Mathieu Fauriat, Cyril Dulphy, Nicolas Toubert, Antoine Luche, Herve Malissen, Marie Blaise, Didier Nunès, Jacques A. Vey, Norbert Olive, Daniel |
author_sort | Chretien, Anne-Sophie |
collection | PubMed |
description | Natural killer (NK) cells are major antileukemic immune effectors. Leukemic blasts have a negative impact on NK cell function and promote the emergence of phenotypically and functionally impaired NK cells. In the current work, we highlight an accumulation of CD56(−)CD16(+) unconventional NK cells in acute myeloid leukemia (AML), an aberrant subset initially described as being elevated in patients chronically infected with HIV-1. Deep phenotyping of NK cells was performed using peripheral blood from patients with newly diagnosed AML (n = 48, HEMATOBIO cohort, NCT02320656) and healthy subjects (n = 18) by mass cytometry. We showed evidence of a moderate to drastic accumulation of CD56(−)CD16(+) unconventional NK cells in 27% of patients. These NK cells displayed decreased expression of NKG2A as well as the triggering receptors NKp30 and NKp46, in line with previous observations in HIV-infected patients. High-dimensional characterization of these NK cells highlighted a decreased expression of three additional major triggering receptors required for NK cell activation, NKG2D, DNAM-1, and CD96. A high proportion of CD56(−)CD16(+) NK cells at diagnosis was associated with an adverse clinical outcome and decreased overall survival (HR = 0.13; P = 0.0002) and event-free survival (HR = 0.33; P = 0.018) and retained statistical significance in multivariate analysis. Pseudotime analysis of the NK cell compartment highlighted a disruption of the maturation process, with a bifurcation from conventional NK cells toward CD56(−)CD16(+) NK cells. Overall, our data suggest that the accumulation of CD56(−)CD16(+) NK cells may be the consequence of immune escape from innate immunity during AML progression. |
format | Online Article Text |
id | pubmed-8179170 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | National Academy of Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-81791702021-06-16 High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome Chretien, Anne-Sophie Devillier, Raynier Granjeaud, Samuel Cordier, Charlotte Demerle, Clemence Salem, Nassim Wlosik, Julia Orlanducci, Florence Gorvel, Laurent Fattori, Stephane Hospital, Marie-Anne Pakradouni, Jihane Gregori, Emilie Paul, Magali Rochigneux, Philippe Pagliardini, Thomas Morey, Mathieu Fauriat, Cyril Dulphy, Nicolas Toubert, Antoine Luche, Herve Malissen, Marie Blaise, Didier Nunès, Jacques A. Vey, Norbert Olive, Daniel Proc Natl Acad Sci U S A Biological Sciences Natural killer (NK) cells are major antileukemic immune effectors. Leukemic blasts have a negative impact on NK cell function and promote the emergence of phenotypically and functionally impaired NK cells. In the current work, we highlight an accumulation of CD56(−)CD16(+) unconventional NK cells in acute myeloid leukemia (AML), an aberrant subset initially described as being elevated in patients chronically infected with HIV-1. Deep phenotyping of NK cells was performed using peripheral blood from patients with newly diagnosed AML (n = 48, HEMATOBIO cohort, NCT02320656) and healthy subjects (n = 18) by mass cytometry. We showed evidence of a moderate to drastic accumulation of CD56(−)CD16(+) unconventional NK cells in 27% of patients. These NK cells displayed decreased expression of NKG2A as well as the triggering receptors NKp30 and NKp46, in line with previous observations in HIV-infected patients. High-dimensional characterization of these NK cells highlighted a decreased expression of three additional major triggering receptors required for NK cell activation, NKG2D, DNAM-1, and CD96. A high proportion of CD56(−)CD16(+) NK cells at diagnosis was associated with an adverse clinical outcome and decreased overall survival (HR = 0.13; P = 0.0002) and event-free survival (HR = 0.33; P = 0.018) and retained statistical significance in multivariate analysis. Pseudotime analysis of the NK cell compartment highlighted a disruption of the maturation process, with a bifurcation from conventional NK cells toward CD56(−)CD16(+) NK cells. Overall, our data suggest that the accumulation of CD56(−)CD16(+) NK cells may be the consequence of immune escape from innate immunity during AML progression. National Academy of Sciences 2021-06-01 2021-05-28 /pmc/articles/PMC8179170/ /pubmed/34050021 http://dx.doi.org/10.1073/pnas.2020459118 Text en Copyright © 2021 the Author(s). Published by PNAS. https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Biological Sciences Chretien, Anne-Sophie Devillier, Raynier Granjeaud, Samuel Cordier, Charlotte Demerle, Clemence Salem, Nassim Wlosik, Julia Orlanducci, Florence Gorvel, Laurent Fattori, Stephane Hospital, Marie-Anne Pakradouni, Jihane Gregori, Emilie Paul, Magali Rochigneux, Philippe Pagliardini, Thomas Morey, Mathieu Fauriat, Cyril Dulphy, Nicolas Toubert, Antoine Luche, Herve Malissen, Marie Blaise, Didier Nunès, Jacques A. Vey, Norbert Olive, Daniel High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome |
title | High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome |
title_full | High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome |
title_fullStr | High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome |
title_full_unstemmed | High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome |
title_short | High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome |
title_sort | high-dimensional mass cytometry analysis of nk cell alterations in aml identifies a subgroup with adverse clinical outcome |
topic | Biological Sciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179170/ https://www.ncbi.nlm.nih.gov/pubmed/34050021 http://dx.doi.org/10.1073/pnas.2020459118 |
work_keys_str_mv | AT chretienannesophie highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT devillierraynier highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT granjeaudsamuel highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT cordiercharlotte highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT demerleclemence highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT salemnassim highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT wlosikjulia highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT orlanducciflorence highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT gorvellaurent highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT fattoristephane highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT hospitalmarieanne highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT pakradounijihane highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT gregoriemilie highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT paulmagali highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT rochigneuxphilippe highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT pagliardinithomas highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT moreymathieu highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT fauriatcyril highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT dulphynicolas highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT toubertantoine highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT lucheherve highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT malissenmarie highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT blaisedidier highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT nunesjacquesa highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT veynorbert highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome AT olivedaniel highdimensionalmasscytometryanalysisofnkcellalterationsinamlidentifiesasubgroupwithadverseclinicaloutcome |